HER2 siRNA Facilitated Gene Silencing Coupled with Doxorubicin Delivery: A Dual Responsive Nanoplatform Abrogates Breast Cancer
- Title
- HER2 siRNA Facilitated Gene Silencing Coupled with Doxorubicin Delivery: A Dual Responsive Nanoplatform Abrogates Breast Cancer
- Creator
- Archana M.G.; Anusree K.S.; Unnikrishnan B.S.; Reshma P.L.; Syama H.P.; Sreekutty J.; Joseph M.M.; Sreelekha T.T.
- Description
- The present study investigated the concurrent delivery of antineoplastic drug, doxorubicin, and HER2 siRNA through a targeted theranostic metallic gold nanoparticle designed using polysaccharide, PSP001. The as-synthesized HsiRNA@PGD NPs were characterized in terms of structural, functional, physicochemical, and biological properties. HsiRNA@PGD NPs exposed adequate hydrodynamic size, considerable ? potential, and excellent drug/siRNA loading and encapsulation efficiency. Meticulous exploration of the biocompatible dual-targeted nanoconjugate exhibited an appealing biocompatibility and pH-sensitive cargo release kinetics, indicating its safety for use in clinics. HsiRNA@PGD NPs deciphered competent cancer cell internalization, enhanced cytotoxicity mediated via the induction of apoptosis, and excellent downregulation of the overexpressing target HER2 gene. Further in vivo explorations in the SKBR3 xenograft breast tumor model revealed the appealing tumor reduction properties, selective accumulation in the tumor site followed by significant suppression of the HER2 gene which contributed to the exclusive abrogation of breast tumor mass by the HsiRNA@PGD NPs. Compared to free drugs or the monotherapy constructs, the dual delivery approach produced a synergistic suppression of breast tumors both in vitro and in vivo. Hence the drawings from these findings implicate that the as-synthesized HsiRNA@PGD NPs could offer a promising platform for chemo-RNAi combinational breast cancer therapy. 2024 American Chemical Society.
- Source
- ACS Applied Materials and Interfaces, Vol-16, No. 20, pp. 25710-25726.
- Date
- 2024-01-01
- Publisher
- American Chemical Society
- Subject
- breast cancer; doxorubicin; gene-drug co-delivery; HER2 siRNA; RNA interference
- Coverage
- Archana M.G., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India; Anusree K.S., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India; Unnikrishnan B.S., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India, Centre for Nanotechnology, Indian Institute of Technology (IIT), Uttarakhand, Roorkee, 247667, India; Reshma P.L., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India; Syama H.P., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India; Sreekutty J., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India; Joseph M.M., Chemical Sciences & Technology Division (CSTD), Organic Chemistry Section, CSIR-National Institute for Interdisciplinary Science & Technology (CSIR-NIIST), Kerala, Thiruvananthapuram, 695019, India, Department of Life Sciences, CHRIST University, Banglore, 560029, India; Sreelekha T.T., Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC), Kerala, Thiruvananthapuram, 695011, India
- Rights
- Restricted Access
- Relation
- ISSN: 19448244; PubMed ID: 38739808
- Format
- Online
- Language
- English
- Type
- Article
Collection
Citation
Archana M.G.; Anusree K.S.; Unnikrishnan B.S.; Reshma P.L.; Syama H.P.; Sreekutty J.; Joseph M.M.; Sreelekha T.T., “HER2 siRNA Facilitated Gene Silencing Coupled with Doxorubicin Delivery: A Dual Responsive Nanoplatform Abrogates Breast Cancer,” CHRIST (Deemed To Be University) Institutional Repository, accessed February 25, 2025, https://archives.christuniversity.in/items/show/13096.